Literature DB >> 17169538

Warfarin maintenance dose adjustment with indirect pharmacodynamic model in rats.

Yan-Guang Cao1, Xiao-Quan Liu, Yuan-Cheng Chen, Kun Hao, Guang-Ji Wang.   

Abstract

The purpose of the study was to adjust the individual maintenance dose of warfarin with a simple approach based on indirect pharmacodynamic model (IDR). Based on the distinct pharmacokinetic and pharmacodynamic features of warfarin, the relationship between the maintenance dose and the steady-state anticoagulation effect was simplified and an approach for the maintenance dose adjustment was proposed. According to the steady-state anticoagulation effect before and after multiple doses (0.1 mg kg(-1)day(-1)), the optimal maintenance doses were predicted for the target anticoagulation effect (INR(target)=2.5), then the actual anticoagulation effect (prothrombin times, PT) on the 6th (8 pm)\8th (8 am)\10th (2 pm) day after dose adjustment according the present method was compared with the target effects with a view of determination the feasibility and accuracy of the proposed approach. The proposed method was also used to adjust warfarin maintenance doses in the presence of metabolism inhibitor metronidazole. The results suggested that the proposed approach could appropriately achieve the target international normalized ratio (INR(target)) when warfarin used alone or in combination with metronidazole, the actual INR values of three days were 2.69+/-0.18 and 2.52+/-0.22 (mean+/-S.D.), respectively. The method provided a relatively simple and accurate strategy for warfarin maintenance dose adjustment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17169538     DOI: 10.1016/j.ejps.2006.10.009

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  3 in total

1.  Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation.

Authors:  Kyle Ware; Polina Brodsky; Anjali A Satoskar; Tibor Nadasdy; Gyongyi Nadasdy; Haifeng Wu; Brad H Rovin; Udayan Bhatt; Jon Von Visger; Lee A Hebert; Sergey V Brodsky
Journal:  J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 10.121

2.  Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation.

Authors:  Inna Y Gong; Ute I Schwarz; Natalie Crown; George K Dresser; Alejandro Lazo-Langner; GuangYong Zou; Dan M Roden; C Michael Stein; Marc Rodger; Philip S Wells; Richard B Kim; Rommel G Tirona
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

3.  Synthesis and vasorelaxant and platelet antiaggregatory activities of a new series of 6-halo-3-phenylcoumarins.

Authors:  Elías Quezada; Giovanna Delogu; Carmen Picciau; Lourdes Santana; Gianni Podda; Fernanda Borges; Verónica García-Morales; Dolores Viña; Francisco Orallo
Journal:  Molecules       Date:  2010-01-12       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.